Literature DB >> 22736784

'Tumour-induced osteomalacia'.

Javier Munoz1, Rosa Michel Ortega, Florence Celzo, Vijayalakshmi Donthireddy.   

Abstract

A 60-year-old man presented 2 years before his diagnosis with long-standing muscle cramping, progressive generalised weakness and chronic hip pain. The patient was found to have bilateral femoral neck pathologic fractures therefore, underwent reamed intramedullary nailing of both femurs. Laboratory studies showed hypophosphataemia. Bone marrow biopsy was negative for malignancy. Positron emission tomography demonstrated fludeoxyglucose uptake only in the posterior neck. Bone scan showed innumerable foci of increased activity throughout the skeleton consistent with pseudofractures seen in osteomalacia. Fine needle aspiration from the mass in the neck revealed a phosphaturic mesenchymal tumour of mixed connective tissue type. Resection of the mass in the neck resulted in resolution of generalised complaints with no evidence of recurrence with a follow-up of 12 months.

Entities:  

Mesh:

Year:  2012        PMID: 22736784      PMCID: PMC3448346          DOI: 10.1136/bcr.03.2012.5975

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

Review 2.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

3.  Phosphaturic mesenchymal tumour-mixed connective tissue variant without oncogenic osteomalacia.

Authors:  R Winters; S Bihlmeyer; L McCahill; K Cooper
Journal:  J Clin Pathol       Date:  2009-08       Impact factor: 3.411

4.  Tumor-induced osteomalacia: a case report.

Authors:  Daniel Dutra Romualdo-Silva; Bárbara Campolina Carvalho Silva; Cristiane Vasconcelos Caetano; Angélica Maria França Paiva Tibúrcio; Maurício Buzelin Nunes; Sérgio Almeida Pinheiro Chagas; Elizandra Tomazela Laurenti Polito; Antônio Rodrigues Ferreira; Saulo Purisch
Journal:  Arq Bras Endocrinol Metabol       Date:  2009-04

5.  Coexistence of tumor-induced osteomalacia and primary hyperparathyroidism.

Authors:  Athina Markou; Vassiliki Tsiama; Symeon Tournis; Labrini Papanastasiou; Vaios Tsiavos; Aikaterini Dassou; Vasiliki Vlachou; Eugenia Papaliodi; Niki Asimaki; George Zografos; George Piaditis
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

6.  Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography.

Authors:  Eric Hesse; Eckart Moessinger; Herbert Rosenthal; Florian Laenger; Georg Brabant; Thorsten Petrich; Klaus F Gratz; Leonard Bastian
Journal:  J Bone Miner Res       Date:  2007-01       Impact factor: 6.741

7.  Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.

Authors:  Yoshiyuki Mori; Toru Ogasawara; Toru Motoi; Yuichiro Shimizu; Daichi Chikazu; Kazumi Tamura; Seiji Fukumoto; Tsuyoshi Takato
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-03

Review 8.  Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

  8 in total
  2 in total

1.  Acquired hypophosphatemic osteomalacia is easily misdiagnosed or neglected by rheumatologists: A report of 9 cases.

Authors:  Ling Li; Shu-Xia Wang; Hong-Mei Wu; Dong-Lan Luo; Guang-Fu Dong; Yuan Feng; Xiao Zhang
Journal:  Exp Ther Med       Date:  2018-04-27       Impact factor: 2.447

2.  Tumor induced osteomalacia in head and neck region: single center experience and systematic review.

Authors:  Ravikumar Shah; Anurag R Lila; Ramteke-Swati Jadhav; Virendra Patil; Abhishek Mahajan; Sushil Sonawane; Puja Thadani; Anil Dcruz; Prathamesh Pai; Munita Bal; Subhada Kane; Nalini Shah; Tushar Bandgar
Journal:  Endocr Connect       Date:  2019-10       Impact factor: 3.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.